ArticleCommunications medicine2026
Blood metal signatures and their association with Alzheimer's disease risk and cognitive decline in an Egyptian cohort.
Article in Communications medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlzheimer's disease (AD) is a multifactorial disease in which environmental exposures may contribute to disease risk. This study aimed to investigate associations between blood concentrations of arsenic, lead, mercury, and lithium with AD risk and cognitive performance in an Egyptian cohort.
methodsWe conducted a cross-sectional study in 50 AD patients and 50 cognitively healthy controls recruited across multiple centres in Egypt. Blood metal concentrations were measured by inductively coupled plasma optical emission spectrometry. A tiered analytical strategy addressed variable left-censoring: group-stratified Kaplan-Meier imputation was applied for arsenic, lead, and lithium, followed by logistic and linear regression adjusted for age and sex, with a binary detection sensitivity analysis for lithium, lead, and mercury. Multiple testing was corrected using the Benjamini-Hochberg false discovery rate method.
resultsHere we show that higher arsenic concentrations are strongly associated with increased odds of AD (OR = 1321.61, p = 3.48×10⁻⁶) and lower cognitive scores (β = -16.44, p = 1.46×10⁻⁸), both surviving false discovery rate correction. Higher lithium is associated with reduced disease odds (OR = 0.634, FDR-adjusted p = 0.022) and better cognitive performance (β = 1.21, FDR-adjusted p = 0.020), corroborated in sensitivity analyses. Mercury detection is markedly more frequent in patients than controls (24% vs. 2%, p = 0.002) and associates with lower cognitive scores (β = -7.08, p = 0.0003). Lead shows a borderline association with disease (OR = 1.53, p = 0.046) that does not survive correction.
conclusionsThese findings support arsenic neurotoxicity and lithium deficiency as potentially important contributors to AD risk in an Egyptian population, with implications for environmental public health in low- and middle-income settings.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.